Childhood acute lymphoblastic leukaemia and relapse (Q36340652)

13 August 2017

1 reference

title

Childhood acute lymphoblastic leukaemia and relapse (English)

1 reference

13 August 2017

1 reference

1

Paul S Gaynon

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

British Journal of Haematology

13 August 2017

published in

1 reference

13 August 2017

volume

131

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

579-587

1 reference

Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Late effects among survivors of leukemia during childhood and adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Bevacizumab: antiangiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Therapeutic potential of target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

All children have a right to full access to treatment for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

The national cancer data base report on patterns of childhood cancers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Overview of the clinical efficacy of investigational anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Lymphoma: diagnosis, staging, natural history, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2005.05773.X

10.1111/J.1365-2141.2005.05773.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference